Le Lézard
Classified in: Health, Business
Subjects: NEW PRODUCTS/SERVICES, BUSINESS CONTRACTS

Blissco Signs Supply Agreement with Alberta Gaming, Liquor and Cannabis (AGLC)


Not for distribution in the U.S. or to U.S. Newswires

VANCOUVER, British Columbia, March 18, 2019 (GLOBE NEWSWIRE) -- Blissco Cannabis Corp. (CSE: BLIS) (OTCQB: HSTRF) (FRA: GQ4B), ("Blissco") or the ("Company") is a Canadian cannabis brand based in British Columbia, a licensed processor and producer of premium dried cannabis and cannabis oil, and a licensed distributor of dried cannabis products. The Company is pleased to announce that it has signed a supply agreement with AGLC that includes renewal options.

Blissco will enter the Alberta recreational cannabis market, supplying the province initially with three strains from their whole flower collection. Blissco products will be available at Alberta retail locations and on albertacannabis.org. "Alberta has the highest cannabis retail sales in Canada, and we are excited for the opportunity to supply this growing market with our premium dried cannabis and offer cannabis extract products later in 2019," said Damian Kettlewell, Blissco CEO.

Blissco's list of supply agreements continues to expand as the company now has agreements to supply the British Columbia, Saskatchewan and Alberta markets domestically and the German market internationally. "We look forward to continuing to add to our customer list as we meet with more provinces as well as international partners," adds Kettlewell.

CTV reported that in the first months following Canada's legalization of cannabis the nation has recorded more than $150 million in retail sales with Alberta posting the highest retail sales numbers. 

About Blissco Cannabis Corp.

Blissco Cannabis Corp. (CSE: BLIS) (OTCQB: HSTRF) (FRA: GQ4B) is a Canadian wellness cannabis brand based in British Columbia and a multi-licensed processor, cultivator, and distributor of premium cannabis.

Blissco owns and operates an 18,000 square foot, state-of-the-art GPP facility located in Metro Vancouver, British Columbia with extraction, cultivation and processing rooms. Blissco is supplying premium cannabis and small-batch Reserve whole flower and dried flower pre-rolls to the Canadian and global marketplace with a growing list of provincial cannabis boards and international distribution partners.

With a licence to process cannabis oil acquired in August 2018, Blissco's extraction lab is also in operation preparing a line of full spectrum oils for distribution in 2019.

Learn more at blissco.com.

?
On Behalf of the Board of Directors

BLISSCO CANNABIS CORP.

Damian Kettlewell, CEO, Founder & Chair

For further information please contact:
1 604 484-9119
[email protected]

Cautionary Statements

This news release contains certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively "forward-looking statements"). The use of any of the word "will" and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Such forward-looking statements should not be unduly relied upon. This news release contains forward-looking statements and assumptions pertaining to the following: the ability to execute on our strategic plans and the impact on our future operations, capital expenditures, receipt of a cannabis oil license and a license to sell dried cannabis and other objectives. Actual results achieved may vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors. The Company believes the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct. The Company does not undertake to update these forward-looking statements, except as required by law.

The CSE has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.


These press releases may also interest you

at 01:17
Quarter 1, 2024 - High profitability and strong cash flow Net sales decreased 4.1% to SEK 34,850m (36,352)Organic growth amounted to -4.0%, of which volume accounted for -1.8% and price/mix -2.2%. Excluding restructuring and exited contracts, volumes...

at 00:05
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...

at 00:05
The Insurance Institute for Highway Safety is updating its vehicle-to-vehicle front crash prevention test to address crashes that occur at higher speeds and those in which the struck vehicle is a motorcycle or large truck. Only one of the first 10...

at 00:00
Nutriessential.com recently announced its expansion into Oceania, Asia, and the Gulf. The company has been providing science-backed GMP-certified supplements in the US, Europe and Canada since 2005 and decided to expand owing to rising global demands...

24 avr 2024
Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones.   During an illustrious 30-year...

24 avr 2024
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...



News published on and distributed by: